EydisBio is an innovative early-stage pharmaceutical company dedicated to the discovery and development of novel, highly selective small molecule therapeutics. Our pioneering, potentially first-in-class TAK1 inhibitor program has demonstrated significant promise in preclinical models of various autoimmune and inflammatory diseases, and has the potential to deliver safer and more effective treatment options for patients suffering from these debilitating conditions.
- Industries
-
Biotechnology
Chemical
Health
Health Care & Hospitals
Medical Pharmaceuticals
Pharmaceuticals
- Contact Information
-
Robert Freeze
Vice President of Business Development
(919) 909-2237
[email protected]
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.
Latest
Journalists and Bloggers
The news you need, when you need it.
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE